Circulating cell-free DNA (ccfDNA) is a promising diagnostic tool and its size fractionation is of interest. However, kits for isolation of ccfDNA available on the market are designed for small volumes hence processing large sample volumes is laborious. We have tested a new method that enables enrichment of ccfDNA from large volumes of plasma and subsequently allows size-fractionation of isolated ccfDNA into two fractions with individually established cut-off levels of ccfDNA length. This method allows isolation of low-abundant DNA as well as separation of long and short DNA molecules. This procedure may be important e.g., in prenatal diagnostics and cancer research that have been already confirmed by our primary experiments. Here, we report the results of selective separation of 200- and 500-bp long synthetic DNA fragments spiked in plasma samples. Furthermore, we size-fractionated ccfDNA from the plasma of pregnant women and verified the prevalence of fetal ccfDNA in all fractions.

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-42044-8_30DOI Listing

Publication Analysis

Top Keywords

ccfdna fractions
8
ccfdna
7
dna
5
novel technology
4
technology enrichment
4
enrichment biomolecules
4
biomolecules cell-free
4
cell-free body
4
body fluids
4
fluids subsequent
4

Similar Publications

Article Synopsis
  • Circulating cell-free DNA (ccfDNA) of mitochondrial origin (ccf-mtDNA) is a small part of the total ccfDNA in bodily fluids, with abnormal levels linked to various diseases.
  • A new standardized dual-qPCR assay effectively measures nuclear and mitochondrial ccfDNA, revealing that high ccf-mtDNA levels are significant in Breast Cancer and Type 2 Diabetes, but not in Osteoarthritis.
  • Machine learning was applied to create biosignatures for diagnosing and predicting outcomes in these diseases, highlighting their potential in improving clinical management.
View Article and Find Full Text PDF

The Position of Circulating Tumor DNA in the Clinical Management of Colorectal Cancer.

Cancers (Basel)

February 2023

UMR-S1138, CNRS SNC5096, Équipe labélisée Ligue Nationale Contre le Cancer, Centre de Recherche des Cordeliers, Université de Paris, 75006 Paris, France.

Colorectal cancer (CRC) is the third most common cancer type worldwide, with over 1.9 million new cases and 935,000 related deaths in 2020. Within the next decade, the incidence of CRC is estimated to increase by 60% and the mortality by 80%.

View Article and Find Full Text PDF

Context: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant disease caused by inactivating mutations in the MEN1 gene. In the literature, few cases of MEN1 have been reported because of mosaic MEN1 mutations.

Objective: We performed an extensive molecular characterization in several lesions and blood samples, including plasmatic circulating cell-free DNA (ccfDNA) in an exceptional case of a patient with MEN1 mosaicism causing primary hyperparathyroidism, multiple pancreatic neuroendocrine tumors (NETs), and a metastatic thymic NET.

View Article and Find Full Text PDF

Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis.

J Mol Diagn

November 2021

Division of Hematology-Oncology, Department of Medicine, Raymond and Ruth Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address:

Circulating cell-free DNA (ccfDNA) is used increasingly as a cancer biomarker for prognostication, as a correlate for tumor volume, or as input for downstream molecular analysis. Determining optimal blood processing and ccfDNA quantification are crucial for ccfDNA to serve as an accurate biomarker as it moves into the clinical realm. Whole blood was collected from 50 subjects, processed to plasma, and used immediately or frozen at -80°C.

View Article and Find Full Text PDF

Circulating cell-free DNA (ccfDNA), released from normal and cancerous cells, is a promising biomarker for cancer detection as in neoplastic patients it is enriched in tumor-derived DNA (ctDNA). ctDNA contains cancer-specific mutations and epigenetic modifications, which can have diagnostic/prognostic value. However, in primary tumors, and in particular in localized prostate cancer (PCa), the fraction of ctDNA is very low and conventional strategies to study ccfDNA are unsuccessful.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!